Skip to content

Sleep's Influence on the Treatment of Intrusive Emotional

Sleep's Influence on the Treatment of Intrusive Emotional Memories With Trauma-focused CBT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05678361
Acronym
SLEPT
Enrollment
42
Registered
2023-01-10
Start date
2018-08-01
Completion date
2022-12-01
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrusive Memories, PTSD

Keywords

sleep, memory, consolidation

Brief summary

Intrusive memories represent a debilitating core feature of PTSD, one of the most prevalent psychiatric disorders following trauma. Exposure therapy is amongst the most successful treatments of PTSD that is recommended by most of the current national and international guidelines. The current study aims to test whether sleep as adjunct to written exposure sessions, a type of exposure- based treatment for PTSD, may boost the effectiveness of the therapy.

Detailed description

Intrusive memories represent a debilitating core feature of PTSD, one of the most prevalent psychiatric disorders following trauma. Exposure therapy is amongst the most successful treatments of PTSD that is recommended by most of the current national and international guidelines. However, not all patients benefit equally and only about 50% show sustained response. There is thus room for improvement in terms of (i) better understanding who benefits from this type of therapy and (ii) possible ways of augmenting existing trauma-focused therapies. The current study aims to contribute to these endevours. Specifically, the study aims to test whether sleep as adjunct to written exposure sessions, a type of exposure- based treatment for PTSD, may boost the effectiveness of the therapy.

Interventions

BEHAVIORALSleep/Nap

Participants sleep after a maximum of three sessions of exposure therapy.

Sponsors

Psychiatric University Hospital, Zurich
CollaboratorOTHER
University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Masking description

Psychotherapists and outcome assessors are blind to participants' group membership (i.e., sleep versus wake after exposure therapy)

Intervention model description

Randomised controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* DSM V criteria of PTSD (at least moderate symptoms in two categories) * Currently receiving Written Exposure Therapy at one of the psychotherapy centers at the Psychiatric University Clinic (PUC). * Not more than moderate alcohol consumption (not more than 5 alcoholic drinks/week). * Ability to understand the study instructions

Exclusion criteria

* Travel over \> 3 time zones in \< 3 months * head injury * shift work * current substance abuse * neurological disease * drug addiction * Current suicidality Specific

Design outcomes

Primary

MeasureTime frameDescription
Self-reported Posttraumatic stress symptom severity at 1 monthOne month post- treatmentSelf - reported PTSD symptom severity (PCL-5)
Clinician- assessed Posttraumatic stress symptom severity at 1 weekOne week post- treatmentClinician- assessed PTSD symptom severity (CAPS- 5)
Self-reported Posttraumatic stress symptom severity at 1 weekOne week post- treatmentSelf - reported PTSD symptom severity (PCL-5)
Clinician- assessed Posttraumatic stress symptom severity at 1 monthOne month post- treatmentClinician- assessed PTSD symptom severity (CAPS- 5)

Secondary

MeasureTime frameDescription
Total sleep timeImmediately after written exposure therapyTotal sleep time according to EEG
Time spent in N1 sleepImmediately after written exposure therapyN1 time according to EEG
Time spent in N2 sleepImmediately after written exposure therapyN2 time according to EEG
Time spent in N3 sleepImmediately after written exposure therapyN3 time according to EEG

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026